Przejdź do zawartości
Merck

C3160

Complement C5 from human serum

≥90% (SDS-PAGE), >100,000 C5H50 units/mg protein

Synonim(y):

C5 human, Complement C5

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

0.1 MG

1560,00 zł

1560,00 zł


Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Zamów zamówienie zbiorcze

Informacje o tej pozycji

Numer CAS:
UNSPSC Code:
12352202
NACRES:
NA.71
MDL number:
Form:
solution
Assay:
≥90% (SDS-PAGE)
Biological source:
human serum

Przejdź do

Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc

biological source

human serum

assay

≥90% (SDS-PAGE)

form

solution

specific activity

>100,000 C5H50 units/mg protein

concentration

1 mg/mL in PBS, pH 7.2

technique(s)

activity assay: suitable

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Quality Level

Gene Information

human ... C5(727)

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 4

Ta pozycja
C1163C2787C2910
biological source

human serum

biological source

human

biological source

human serum

biological source

human

technique(s)

activity assay: suitable

technique(s)

activity assay: suitable

technique(s)

activity assay: suitable

technique(s)

activity assay: suitable

assay

≥90% (SDS-PAGE)

assay

-

assay

≥85% (SDS-PAGE)

assay

≥85% (SDS-GE)

concentration

1 mg/mL in PBS, pH 7.2

concentration

-

concentration

1 mg/mL in 10 mM sodium phosphate, 150 mM sodium chloride, pH 7.2

concentration

-

form

solution

form

solution

form

solution

form

solution

UniProt accession no.

P01031

UniProt accession no.

P01031

UniProt accession no.

P10643

UniProt accession no.

P01024

Application

Complement C5 is part of the terminal sequence in the complement pathway. In particular, it is cleaved into C5a and C5b which are responsible for chemotaxis, inflammation, and initiating the formation of the membrane attack complex (MAC). Drugs that inhibit complement C5 have been used in Paroxysmal nocturnal hemoglobinuria (PNH) patients to lessen thrombotic complications by lessening intravascular hemolysis.

Biochem/physiol Actions

Complement component C5 is processed by convertase enzymes in a cascade modulated in a unique way. The multi-subunit catalytic complex initially shows little activity against C5, but instead cleaves C3. A C3 cleavage product C3b covalently attaches to the complex and shifts its specificity to C5 by a factor of 1000.

Analysis Note

Functionally active by a sensitive hemolytic assay.

Other Notes

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Klasa składowania

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

The role of complement inhibition in PNH.
Hillmen P.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2008(1), 116-123 (2008)
A M Risitano et al.
Mini reviews in medicinal chemistry, 11(6), 528-535 (2011-05-13)
Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder characterized by complementmediated hemolytic anemia, thrombophilia and bone marrow failure. The clinical hallmark of PNH is evident chronic hemolysis due to the absence of the complement regulators CD55 and CD59 on PNH
Peter Hillmen et al.
The New England journal of medicine, 350(6), 552-559 (2004-02-06)
Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement

Questions

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej